More recently, the FDA has approved inavolisib for PIK3CA mutated HR+ HER2- BC along with its companion diagnostic device, the FoundationOne Liquid CDx assay (Foundation Medicine, Inc. Cambridge, MA USA) [22]. This evidence concerns the gene PIK3CA and breast cancer.